Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_3
1
13%
Ph phase_1
1
13%
Ph phase_2
6
75%

Phase Distribution

1

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
6(75.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Other(2)

Detailed Status

Completed5
unknown2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 26 (75.0%)
Phase 31 (12.5%)

Trials by Status

enrolling_by_invitation113%
completed563%
unknown225%

Recent Activity

0 active trials
Showing 5 of 8
enrolling_by_invitationphase_1

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

NCT07210047
completedphase_3

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03952091
unknownphase_2

Lenalidomide and Dexamethasone for Rosai-Dorfman Disease

NCT04924647
completedphase_2

POEMS Syndrome Treatment With Lenalidomide

NCT01639898
completedphase_2

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

NCT00807599
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07210047Phase 1

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

Enrolling By Invitation
NCT03952091Phase 3

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Completed
NCT04924647Phase 2

Lenalidomide and Dexamethasone for Rosai-Dorfman Disease

Unknown
NCT01639898Phase 2

POEMS Syndrome Treatment With Lenalidomide

Completed
NCT00807599Phase 2

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Completed
NCT01270932Phase 2

Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients

Completed
NCT01133743Phase 2

Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia

Completed
NCT00971685Phase 2

The Treatment of Lenalidomide in Patients With POEMS Syndrome

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8